THALES
29.4.2021 10:02:07 CEST | Business Wire | Press release
To guarantee security and complete control of data, Thales and OVHcloud have joined forces to offer Citadel Team encrypted messaging customers a trusted hosting platform that guarantees the sovereignty of their data. Citadel Team customers' data is encrypted and stored at OVHcloud, via its own datacenters located in France.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210429005027/en/
Cybercriminals are taking advantage of the Covid-19 pandemic to infiltrate enterprise networks through vulnerabilities created by the large numbers of people working from home. With the sharp rise in cyberattacks — there have been four times the number of attacks in 2020 than in 2019 according to ANSSI , France’s national agency for information system security. There has also been a growing demand for greater security on data sharing and communication apps; it is more important than ever for companies and users to protect their information, encrypt their data and suitable hosting solution to control how it is stored.
Thales offers professionals a secure instant messaging service, Citadel Team, which requires users to register with a company email address. Already adopted by over a third of CAC 40 companies, the service includes the encryption system used by 50 NATO countries. It provides the guarantee that a company’s data will not be used or sold to third parties. It also ensures that all data is stored in France and that the organization can easily manage user devices themselves. Based on these guarantees, the Citadel development teams have recently obtained the France Cybersecurity 2021 label *.
Citadel Team’s new partner, OVHcloud, shares the same values ofsecurity, sovereignty and data protection. Hosting Citadel Team data in OVHcloud's data centers in France is a guarantee for customers of the application to benefit from an environment of trust. OVHcloud relies on an integrated model that gives it complete control over its value chain: from the design of its servers to the construction and management of its data centers, not forgetting the orchestration of its fiber optic network.
Available free of charge, Citadel Team offers users end-to-end encrypted messaging and voice services on a smartphone or computer, plus a host of premium services, including videoconferencing, group calls and screen sharing. Citadel Team continues to add new functionality tailored to the communication requirements of professionals to offer an all-in-one communication solution without sacrificing data security or usability. Citadel Team is also a member of the Open Trusted Cloud programme, initiated by OVHcloud to federate an ecosystem of trusted players and solutions that respect data protection laws.
“We are especially proud to announce this partnership to our customers and the general public. Thales and OVH have been trusted partners for many years, and by combining our strengths under this new hosting arrangement, we are taking the sovereign Citadel Team solution to the next level to offer our customers the very best data hosting option available.” Pierre-Yves Jolivet, Vice President, Cyber Defence Solutions, Thales.
« We welcome Thales' choice to host Citadel Team data on OVHcloud infrastructures. The combination of our strengths is good news for users looking for guarantees that their data will be respected. They can now be sure to benefit from an alternative, trusted and secure end-to-end solution.» Caroline Comet-Fraigneau, VP France and Benelux, OVHcloud
* The label «France Cybersecurity », is a guarantee for users that the products and services bearing the label are French and that they have clear and well-defined functionalities, with a level of quality attested by an independent jury.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
PLEASE VISIT
Thales Group
Defence and Security | Thales Group
View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
